Showing 2571-2580 of 5799 results for "".
- Gryphon Acquires Roc Skincare from J & Jhttps://practicaldermatology.com/news/gryphon-acquires-roc-skincare-from-j-j/2459930/Gryphon Investors has acquired RoC Skincare from Johnson & Johnson Consumer, Inc. The transaction is Gryphon's second investment in the beauty sector after the firm acquired indie color cosmet
- Study: States with Fewer Melanoma Diagnoses Have Higher Death Rateshttps://practicaldermatology.com/news/study-states-with-fewer-melanoma-diagnoses-have-higher-death-rates/2459937/States with fewer melanoma diagnoses actually have higher death rates, report researchers at University of Utah Health. The researchers conducted a state-by-state analysis to understand the geographic disparities for patients diagnosed with melanoma. They found lower survival is associate
- Dermatology Hall of Fame to Recognize Industry Pioneershttps://practicaldermatology.com/news/dermatology-hall-of-fame-to-recognize-industry-pioneers/2459941/The Dermatology Hall of Fame will honor its first inductees February 28, 2019, in Washington, DC. The organization, founded in 2018, was established to recognize and honor past and present luminaries within all areas of dermatology. “The field of dermatology has been furthered by tr
- “Outstanding Clearance Rates” for Sebaceous Hyperplasia Facial Lesions Seen with NPShttps://practicaldermatology.com/news/outstanding-clearance-rates-for-sebaceous-hyperplasia-facial-lesions-seen-with-nps/2459943/Pulse Biosciences' Nano-Pulse Stimulation (NPS) technology achieved “outstanding clearance rates” on sebaceous hyperplasia lesions on the face, the company reports. Initial data indicate that 221 of 222 (99.5 percent
- “Christmas Berry” Plant Compound Could Fight Uveal Melanomahttps://practicaldermatology.com/news/christmas-berry-plant-compound-could-fight-uveal-melanoma/2459945/A compound extracted from the Christmas berry primrose plant may stops the growth of uveal melanoma, according to preliminary tests. With further testing, the discovery could lead to new therapeutic options for patients with uveal melanoma, report researches from the
- RealSelf Forms Strategic Medical Advisory Councilhttps://practicaldermatology.com/news/realself-forms-strategic-medical-advisory-council/2457540/RealSelf, Inc. has formed a Strategic Medical Advisory Council with three operating boards. The RealSelf Strategic Advisory Council is made up of the Business Advisory Board, the Medical Review Advisory Board and the Industry Advisory Board, all of which are comprised of board-certified doctors a
- Asana Biosciences Gets Fast Track Designation from FDA for Dual JAK/SYK Inhibitor for ADhttps://practicaldermatology.com/news/asana-biosciences-gets-fast-track-designation-from-fda-for-dual-jaksyk-inhibitor-for-ad/2457550/The FDA has granted Fast Track designation to Asana BioSciences’ investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. “We are pleased that the FDA has granted Fast Track
- Low 3% Keloid Recurrence Found in Multicenter Case Series of Patients Treated with SRThttps://practicaldermatology.com/news/low-3-keloid-recurrence-found-in-multicenter-case-series-of-patients-treated-with-srt/2457488/Sensus Healthcare, Inc., a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), shared positive results of a multicenter case series of patients treated with the SRT-100 following
- New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approachhttps://practicaldermatology.com/news/new-psa-guidelines-from-national-psoriasis-and-rheumatology-orgs-recommend-treat-to-target-approach/2457490/Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approach for all patients with active PsA. What’s more, the guidelines co
- Crown Laboratories Acquires Select Healthcare Brands from GlaxoSmithKlinehttps://practicaldermatology.com/news/crown-laboratories-acquires-select-healthcare-brands-from-glaxosmithkline/2457492/Crown Laboratories, Inc. has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK). The acquired portfolio includes: PanOxyl® daily acne wash, Sarna® anti-itch lotion, Zeasorb® anti-fungal and prevention product, De